×
Dare Bioscience Price to Free Cash Flow Ratio 2013-2024 | DARE
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Dare Bioscience price to free cash flow ratio from 2013 to 2024. Price to free cash flow ratio can be defined as
View More
Dare Bioscience Price to Free Cash Flow Ratio 2013-2024 | DARE
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Dare Bioscience price to free cash flow ratio from 2013 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$171.8B
Vertex Pharmaceuticals (VRTX)
$117.5B
Regeneron Pharmaceuticals (REGN)
$111.6B
Bristol Myers Squibb (BMY)
$109.4B
Gilead Sciences (GILD)
$105.3B
CSL (CSLLY)
$95.7B
GSK (GSK)
$80.5B
Alnylam Pharmaceuticals (ALNY)
$34.4B
Argenex SE (ARGX)
$31.7B
BioNTech SE (BNTX)
$29.2B
Biogen (BIIB)
$27B
BeiGene (BGNE)
$23.9B
Moderna (MRNA)
$23.1B
Illumina (ILMN)
$22.5B
Genmab (GMAB)
$15.5B
BioMarin Pharmaceutical (BMRN)
$13.2B
Incyte (INCY)
$13B
Exact Sciences (EXAS)
$12.6B
Vaxcyte (PCVX)
$12.4B
Insmed (INSM)
$12.4B
Bio-Techne Corp (TECH)
$11.9B
Sarepta Therapeutics (SRPT)
$11.5B
QIAGEN (QGEN)
$9.9B
Bio-Rad Laboratories (BIO.B)
$9.3B
Legend Biotech (LEGN)
$8.9B
Roivant Sciences (ROIV)
$8.4B
Ascendis Pharma (ASND)
$8.3B
Revolution Medicines (RVMD)
$7.9B
Intra-Cellular Therapies (ITCI)
$7.7B
Repligen (RGEN)
$7.7B